Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

<< Previous

Bullboard Posts

Next >>

Comment by Riverfolkon Apr 07, 2023 9:33am

59 Views

Post# 35384514

RE:RE:RE:RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

Thank you for speaking honestly and with hostility this morning as it lets the readers understand your motives. I will continue to support the facts and provide links to back them up.

As the Prime Minister of Canada states , Arch received funding based on the advice of leading experts in the field.

Prime Minister Trudeau

After showing a signal in the Phase II trials the government reviewed the Data and awarded further funding.

https://archbiopartners.com/2021/12/01/arch-biopartners-lead-drug-lsalt-peptide-to-enter-the-canadian-treatments-for-covid-19-catco-trial/

Last year an Executive from Novo Nordisk joined Arch as a Strategic Advisor

https://archbiopartners.com/2022/10/05/arch-biopartners-adds-farris-smith-as-a-strategic-advisor/

Soon after, the government provided additional funding for the new mechanism of action.

https://archbiopartners.com/2023/02/07/arch-scientist-awarded-cihr-grant-to-study-the-role-of-dipeptidase-1-in-chronic-kidney-disease/

Recently , the government provided 4 million dollars in additional funding to be used for drug manufacturing, dose escalation and additional human trials

https://archbiopartners.com/2023/03/23/arch-biopartners-receives-funding-for-development-of-lsalt-peptide-drug-program/

Have a great day!

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions